← Eichor
Condition: Platinum Resistance Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Platinum Resistance

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Phase 1 · 1 location(s) · Ascentage Pharma Group Inc. · NCT06687070Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06305299A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Phase 1 · 15 location(s) · OnCusp Therapeutics, Inc. · NCT06234423Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Phase 1 · 27 location(s) · National Cancer Institute (NCI) · NCT04633239Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Phase 2 · 16 location(s) · MacroGenics · NCT06730347A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Phase 1 · 15 location(s) · Stemline Therapeutics, Inc. · NCT07226427Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant R
Phase 2 · 1 location(s) · Jiangxi Provincial Cancer Hospital · NCT06259721Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Beva
Phase 3 · 32 location(s) · Genelux Corporation · NCT05281471A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanc
Phase 1 · 12 location(s) · Whitehawk Therapeutics, Inc. · NCT07444814AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Can
Phase 3 · 299 location(s) · AstraZeneca · NCT07218809Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Perito
Phase 3 · 1 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06834672ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
Phase 2 · 2 location(s) · Ira Winer · NCT04055649Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Phase 1 · 2 location(s) · Dana-Farber Cancer Institute · NCT06321484A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
Phase 2 · 17 location(s) · Shanghai Jiaolian Drug Research and Development Co., Ltd · NCT06434610Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Phase 2 · 54 location(s) · Regeneron Pharmaceuticals · NCT06787612Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Phase 2 · 17 location(s) · Cybrexa Therapeutics · NCT06315491A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
Phase 1 · 17 location(s) · NextCure, Inc. · NCT06792552Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.
Phase 2 · 1 location(s) · Fujian Cancer Hospital · NCT05753826A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovari
Phase 3 · 5 location(s) · GlaxoSmithKline · NCT07286266A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer
Phase 1/Phase 2 · 13 location(s) · Nanjing Leads Biolabs Co.,Ltd · NCT07042802First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Incl
Phase 1 · 6 location(s) · Accent Therapeutics · NCT06799065A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent
Phase 3 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06994195A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
Phase 1 · 7 location(s) · Epsilogen Ltd · NCT06547840Platino-resistance in Ovarian Cancer
NA · 1 location(s) · Institut Claudius Regaud · NCT03954171Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovaria
Phase 3 · 178 location(s) · Incyte Corporation · NCT07214779A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
Phase 2 · 1 location(s) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · NCT06522828A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Gr
Phase 2 · 52 location(s) · AbbVie · NCT06682988
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.